Meridigen Biotech Co., Ltd. (Meridigen) is dedicated to developing mesenchymal stem cells (MSCs)-based technologies from manufacturing, characterization, storage, to drug discoveries. Moreover, we have been acquiring other avant-garde technologies, such as machine learning and artificial intelligence, to strive toward invention of smart medical products for the improvement of innovation and precision of medicine. Meridigen’s MSC drugs strictly follow the international standard of Pharmaceutical Inspection Co-operation Scheme Good Manufacturing Practice (PIC/S GMP). Whereby, we have optimized the large-scale manufacturing process, from the raw materials to the final products. It also complies with TFDA’s regulations “Guideline on human cell-based medicinal products” and “Guidelines on the clinical applications of human cell-based medicinal products”. Besides, the manufacturing process has many steps of tests that have been referred to the drug regulatory of FDA, MFDS (Korea), and EU, to ensure the quality of our products is following the GMP standard of these developed countries.

Meridigen was founded in Taiwan, yet with an aim to harbor the world. Being led by the founder John Hsuan (Min-Chih Hsuan) and Chairman Yogi Hsuan, the company has been actively contributed and expanded to the stem cell industry, establishing the largest bank for placenta and umbilical cord derived stem cells in the Chinese world. Meridigen targets this niche market in cooperation with cross- straits industry and academics, to push precision medicine to another level and to discover the potential of stem cell drugs. We strive toward the launch of our stem cell drugs that can benefit the global well-beings of mankind.